Agomab Therapeutics (AGMB) director details sizable stock option grants

Rhea-AI Filing Summary

Agomab Therapeutics NV director David R. Epstein filed an initial ownership report showing stock options over common shares. He holds options covering 770,671 shares at an exercise price of $2.8100 expiring on July 8, 2034, 217,295 shares at $5.2600 expiring on November 4, 2034, and 38,843 shares at $14.2600 expiring on January 15, 2036. Footnotes describe multi-year vesting schedules and note that common shares may be represented by American Depositary Shares on a one-for-one basis.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Epstein David R

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/08/2034	Common shares(2)	770,671	$2.81(3)	D
Stock Option (Right to Buy)	(1)	11/04/2034	Common shares(2)	217,295	$5.26(3)	D
Stock Option (Right to Buy)	(4)	01/15/2036	Common shares(2)	38,843	$14.26(3)	D

Explanation of Responses:

1. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does David R. Epstein report in his Agomab Therapeutics (AGMB) Form 3 filing?

David R. Epstein reports his initial holdings of stock options in Agomab Therapeutics. The filing lists three option awards over common shares with specified exercise prices, expiration dates, and vesting terms, establishing his baseline derivative position as a company director.

How many Agomab Therapeutics shares are covered by David R. Epstein’s stock options?

The filing shows options over 770,671 underlying common shares at $2.8100, 217,295 underlying shares at $5.2600, and 38,843 underlying shares at $14.2600. These figures represent the number of common shares that may be acquired upon exercise, subject to vesting.

What are the exercise prices and expirations of David R. Epstein’s Agomab Therapeutics options?

Epstein’s options have exercise prices of $2.8100, $5.2600, and $14.2600. They expire on July 8, 2034, November 4, 2034, and January 15, 2036, respectively, defining the time window during which the options can be exercised once vested.

How do David R. Epstein’s Agomab Therapeutics options vest according to the Form 3 footnotes?

Footnotes state that for certain options, 50% of underlying shares vested on February 9, 2026, with the remainder vesting in 24 monthly installments, and another grant vests 33% on February 9, 2027 with the rest vesting over 24 months, all contingent on continued service.

Are Agomab Therapeutics common shares in David R. Epstein’s options represented by ADSs?

The filing notes Agomab Therapeutics common shares may be represented by American Depositary Shares. Each ADS currently represents one common share, meaning the reported option holdings correspond one-for-one whether measured in underlying common shares or equivalent ADS units.

In what currency are David R. Epstein’s Agomab Therapeutics option exercise prices reported?

Exercise prices are reported in U.S. dollars. A footnote explains they reflect conversion from euros at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026, providing clarity on how the strike prices were translated from the original currency.